US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Trump Says Anthropic No Longer Seen as National Security Threat 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
TEL AVIV, Israel, Jan. 28, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the BIO CEO and Investor Conference and the 1st Annual Neuroscience BioPartnering & Investment Forum.
| BIO CEO & Investor Conference | |
| Date: | Monday, February 8 |
| Time: | 8:30am ET |
| Location: | Waldorf Astoria, New York, NY |
| 1st Annual Neuroscience BioPartnering & Investment Forum | |
| Date: | Tuesday, February 23 |
| Time: | 4:10pm ET |
| Location: | The New York Academy of Sciences, New York, NY |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
